Evidence map›Paper›PMID 27624712›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Reoperations after primary breast conserving surgery in women with invasive breast cancer in Catalonia, Spain: a retrospective study.

J M Escribà, L Esteban, J Gálvez, M J Pla, A Melià, M Gil-Gil, R Clèries, L Pareja, X Sanz, M Bustins and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

J M EscribàCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain. jmescriba@iconcologia.net.
L EstebanCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
J GálvezCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
M J PlaBreast Cancer Functional Unit, Catalan Institute of Oncology, L' Hospitalet de Llobregat, Barcelona, Spain.
A MeliàCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
M Gil-GilBreast Cancer Functional Unit, Catalan Institute of Oncology, L' Hospitalet de Llobregat, Barcelona, Spain.
R ClèriesCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
L ParejaCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
X SanzCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
M BustinsDivisió d'Anàlisi de la Demanda i l'Activitat, Department of Health, Generalitat de Catalunya, Catalan Health Service, Barcelona, Spain.
J M BorrásCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
J RibesCatalan Cancer Registry, Cancer Planning Directorate, Av. Gran Vía 199-203, L' Hospitalet de Llobregat, 08908, Barcelona, Spain.
Bellvitge University Hospital · ESInstitut Català d'Oncologia · ESGeneralitat de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough complete tumor resection is accepted as the best means to reduce recurrence, reoperations after lumpectomy are a common problem in breast cancer. The aim of this study was to assess the reoperation rates after primary breast conserving surgery in invasive breast cancer cases diagnosed in Catalonia, Spain, between 2005 and 2011 and to identify variations based on patient and tumour characteristics.

methodsWomen with invasive incident breast cancer identified from the Patient's Hospital Discharge Database [174.0-174.9 codes of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) as the primary diagnosis] and receiving primary breast conserving surgery were included in the study and were followed up to 3 and 12 months by collecting information about repeat breast cancer surgery.

resultsReoperation rates after primary breast conserving surgery decreased from 13.0 % in 2005 to 11.7 % in 2011 at 3 months and from 14.2 % in 2005 to 12.9 % in 2011 at 12 months' follow-up. While breast conservation reoperations saw a slight, non-significant increase in the same period (from 5.7 to 7.3 % at 3 months, and from 6.0 to 7.5 % at 12 months), there was a significant decrease in radical reoperation (from 7.3 to 4.4 % at 3 months and from 8.2 to 5.4 % at 12 months). Overall, additional breast surgeries decreased among younger women.

conclusionsDespite the rise of breast conserving surgery, reoperation rates following initial lumpectomy in Catalonia decreased by 10 % at 3 and 12 months' follow-up, remaining low and almost unchanged. Ultimately, there was also a significant decrease in mastectomies.

Indexed as

Mastectomy, SegmentalAgedBreast NeoplasmsCarcinoma, Ductal, BreastFemaleFollow-Up StudiesHumansIncidenceMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisReoperationRetrospective StudiesSpainInvasive breast neoplasmLocal recurrencePartial mastectomyRe-excisionSurgical margins

Identifiers

PMID27624712
OpenAlexW2519861422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.